Corporate Presentation

Safe Harbor

Except for the historical information contained herein, statements in this presentation and the

subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”,

“would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”,

“contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue”

and similar expressions or variations of such expressions may constitute "forward-looking statements".

These forward-looking statements involve a number of risks, uncertainties and other factors that could

cause actual results to differ materially from those suggested by the forward-looking statements. These

risks and uncertainties include, but are not limited to our ability to successfully implement our strategy,

our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological

changes, investment and business income, cash flow projections, our exposure to market risks as well

as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to

reflect events or circumstances after the date thereof.

Mission

“To become a Research-based International

Pharmaceutical Company”

Vision – 2012

Achieve significant business

in proprietary prescription products by 2012

with a strong presence in developed markets

Values

• Achieving customer satisfaction is fundamental to our business

• Provide products and services of the highest quality

• Practice dignity and equity in relationship and provide opportunities for

our people to realise their full potential

• Ensure profitable growth and enhance wealth of the shareholders

• Foster mutually beneficial relations with all our business partners

• Manage our operations with high concern for safety and environment

• Be a responsible corporate citizen

Ranbaxy Overview

• India‟s largest pharmaceutical company

• Ranbaxy & Daiichi Sankyo combined rank among the top 20 global

pharmaceutical companies

• Worldwide Presence

• Ground presence in 46 countries, products sold in over 125 countries

• Manufacturing locations in 7 countries

• Global consolidated sales – US $ 1519 Mn (2009)

• Business

- International 77%

- Domestic 23%

• >13000 employees globally represented by 50 nationalities

Global Pharmaceutical Landscape

Global Pharmaceuticals Market:

• 2009: ~ US $ 727 Bn (+5.7%)

Global Generics Market:

• 2009: US $ 83 Bn (+7.7%)

Key Drivers of Generics:

• Significant patent expiries (~US $

80 Bn drugs) through 2012

• Increasing generic penetration

• Rationalizing healthcare costs

• Emerging markets opportunity

Source : IMS Mat Nov 2009

316

226

152

8033

North America Europe

Africa, Asia and Australia Japan

Latin America

Global Pharma Market Slice

US $ Bn

The Global Generics Advantages

Consolidation

Growth Potential

• Size & Scale

• Therapeutic Width

• Operational Synergies

• Pressure on Vanilla Gx

• Move to Specialty/ Niche

Product Portfolio

• Patent Expiries

• New Markets

• Healthcare Costs

India Factor

• Scientific Talent

• Cost Advantage

• Gx / Rx Competencies

Our Global Presence

• North America

• Latin America

• Europe

• Africa

• Asia (incl. Middle East)

• Japan

Business Model

Global Reach

• Developed Markets

North America, EU, Japan, Australia

• Emerging markets

India, Romania, CIS,

South Africa,

Brazil, Mexico

Manufacturing

Product Portfolio

Research &

Development

• Generics

• Branded Generics

• OTC

• Dosage Form

• API* - Vertical Integration

• In-house / Outsource

• The India advantage

• New Chemical Entities

• Generics / NDDS*

• Complex / Niche/ FTF*

• The India advantage

* NDDS - Novel Drug Delivery System, API – Active Pharmaceutical Ingredients, FTF – First to File

Competitive Advantages

• Aggressive Marketing

• Low cost of Innovation

• Manufacturing Competitiveness

• Global Management

Global Sales Split

* CIS includes Russia & Ukraine belt

Global Sales (2009): US $ 1519 Mn

Asia

Europe

RoW

North

America

CIS*

API

Evolution of Market Mix

Developed

39%

Emerging

54%

Others

7%

FY 2005 FY 2009

• Improving balance in market mix

• Growth well spread across geographies

• Positioned to leverage various market opportunities

Our Key Geographies

Pioneer entrant from India

Strong local presence

Canada: New market, growing rapidly

Well established

Presence in 23 of 27 EU countries

No. 1 Generic player in Romania

Key markets - UK, France & Germany

Leadership in domestic market - India

Estd. Infrastructure in Romania, Brazil, Russia & South Africa

Profitable branded generics markets

North America

EUROPE

Emerging Markets

Developed Markets Presence

• Largest generic market worldwide

• Significant patent expiries through 2012

• Mature generic market

• Ranbaxy is the fastest growing generics company in Canada

USA

Canada

EU

Japan

• Germany, UK - mature markets

• France, Spain, Italy, Romania - emerging markets

• Ranbaxy has presence in 23 of the 27 EU countries

• Emerging generic market, < 5% generic penetration

• 1st Indian pharma company

Emerging Markets Presence

• Leadership position in domestic market

• Company growing faster than market

• Ranked as the No. 1 Generics Company

• Strategic for servicing EU operations

• Strong base in acute therapies

• Fast expanding into chronic and OTC segments

• Key market in the African continent

• A strong No 5 player in the region

India

Romania

Russia &

Ukraine

South Africa

India

• India‟s largest pharmaceutical Company by sales and ranked No. 2 by

market share

• Growing faster than market

• One of the largest distribution networks that comprises 2500+ skilled

field force

• Dedicated task forces for specialised & chronic therapies

• 18 brands in Top 300 of Industry

Research & Development

State-of-the-art R&D facilities

based in India

R&D I

R&D III

R&D II R&D IV

Research & Development

• Dedicated Facilities for Innovative & Generics Research

• > 1200 R&D Personnel

• Highest R&D spender across industry

• Arterolane + PQP (Anti malaria), programs with GSK

• NDDS based products (4 platform technologies)

• R&D collaborations

Alliance /

Collaboration in

NDDR Out-licensing

In NDDS

Out-licensing

In NDDR

Global Manufacturing Strengths

• cGMP compliant world-class API & Dosage Forms manufacturing facilities

across the globe

• 7 manufacturing locations worldwide

• API facilities - increasing vertical integration

• Creating capacities for specialty products

• New facilities added in cost advantageous geographies

India Malaysia

USA Ireland NigeriaRomania

South Africa

Inorganic Strategy

• Size and scale in developed & emerging markets

• Expansion of geographical reach

• Access to niche and complex products / therapeutic areas

• Costs efficiencies in manufacturing and R&D

To capitalize on the opportunities in the ongoing consolidation for…

...providing a strategic and value accretive fit

Acquisitions & Alliances Since 2006

• Terapia (Romania)

• Be-Tabs (South Africa)

• Allen (Italy)

• Ethimed (Belgium)

• Mundogen (Spain)

• Derma Brands (USA)

• Auto-injector Tech (USA)

• Orchid (India)

• Zenotech (India)

• Krebs (India)

• Jupiter (India)

• Cardinal Drugs (India)

• Ochoa Labs (India)

• Biovel (India)

> US $ 500 Mn spend on M&A

Ranbaxy – Daiichi Sankyo Partnership

• A path breaking confluence that redefines the global pharma paradigm

• Combines complementary strengths

• Provides solutions to key need-gaps for each organisation

• Strategic combination creates an Innovator and Generic Pharmaceutical Powerhouse

• Combined entity is ranked among the Top 20 global pharmaceutical companies

• Ranbaxy enters into a new orbit to chart a higher trajectory

• Complementary strengths ranging from excellence in NDDR to extensive reach across global

markets

Complementary Business Combination

Global Pharma Innovator

An Integrated, Research Based,

International Pharmaceutical

Company

• An essential component of Ranbaxy‟s CSR is to care for the

community

• Ranbaxy Rural Development Trust set up in 1978 (later re-

christened as „Ranbaxy Community Health Care Society‟)

• Integrated health care services provided to about 2 lakh

people staying in 110 villages and urban slum areas;

infrastructure includes 14 Mobile Health Care Vans

• Operates in the states of Punjab, Haryana, Himachal

Pradesh, Madhya Pradesh

• Provides a blend of curative, preventive and health

promotive services covering areas of maternal child health,

family planning, adolescent health, reproductive health and

education

Corporate Social Responsibility

• AIDS awareness and counselling is a priority component of

the CSR programme

• Partnerships with Government, Medical Colleges, NGO‟s,

Educational Institutions, Confederation of Indian Industry

and other like minded agencies

• Anti-Aids

– Provides innovative and affordable anti HIV medicines

– Over 5 lakh patients worldwide benefit from Ranbaxy‟s

ARV drugs

– First in the world Pediatrics ARV

• Malaria Research

– Molecule in Phase III Clinical Trials

Corporate Social Responsibility

Corporate Governance

“An institutionalized framework of Corporate Governance and Code of

Practices to strengthen decision making and compliance with ethical

integrity and reliability”

Committees of the Board

Audit

Science

Management

Compensation

Shareholder

Grievance/Transfer

Board Of Directors

Thank You